Can ALK-Abelló’s EURneffy launch shift real-world adoption of non-injectable adrenaline in EU schools?
EMA backs EURneffy 1 mg for pediatric anaphylaxis in EU. Discover how needle-free adrenaline could reshape allergy emergency response today.
Why ALK-Abelló’s investment in Allegria signals a strategic shift in allergic disease treatment
Allegria Therapeutics has secured USD 5.1 million in a seed extension financing round led by ALK-Abelló, with additional participation from HighLight Capital, the Lichtsteiner Foundation, and existing backer Forty51 Ventures. The Swiss biotechnology company will use the funds to nominate its first clinical candidate and advance its portfolio of mast cell-modulating therapies for allergy and […]